4-氟-2-硝基苯甲酸甲酯 | 151504-81-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-2-硝基苯甲酸甲酯
• 中文别名: 2-硝基-4-氟苯甲酸甲酯
• 英文名称: methyl 4-fluoro-2-nitrobenzoate
• CAS: 151504-81-3
• 化学式: C₈H₆FNO₄
• mdl: MFCD09800921
• 分子量: 199.138
• InChiKey: YBAZOLISUXINHV-UHFFFAOYSA-N

物化性质

• 沸点：
  272.1±20.0 °C(Predicted)
• 密度：
  1.388±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 4-fluoro-2-nitrobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 4-fluoro-2-nitrobenzoate
CAS number: 151504-81-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6FNO4
Molecular weight: 199.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

4-氟-2-硝基苯甲酸甲酯可以作为有机合成中间体和医药中间体，主要应用于实验室研发和化工生产过程中。

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  4-氟-2-硝基苯甲酸	4-fluoro-2-nitrobenzoic acid	394-01-4	C7H4FNO4	185.111
  4-氯-2-硝基苯甲酸甲酯	methyl 4-chloro-2-nitrobenzoate	42087-80-9	C8H6ClNO4	215.593
  2,4-二硝基苯甲酸甲酯	2,4-dinitro-benzoic acid methyl ester	18959-17-6	C8H6N2O6	226.145

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	methyl 4-(dimethylamino)-2-nitrobenzoate	773874-70-7	C10H12N2O4	224.216
  ——	4-(3-fluoro-benzyloxy)-2-nitro-benzoic acid methyl ester	713511-19-4	C15H12FNO5	305.262
  ——	4-(3-fluoro-benzyloxy)-2-nitro-benzoic acid (3-fluoro-benzyl) ester	713511-18-3	C21H15F2NO5	399.351
  ——	methyl 4-((2S,6R)-2,6-dimethylmorpholino)-2-nitrobenzoate	1544683-12-6	C14H18N2O5	294.307

反应信息

• 作为反应物：
  描述：

  4-氟-2-硝基苯甲酸甲酯 在 palladium on carbon 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 methyl 2-amino-4-(4-methyl-1,4-diazepan-1-yl)benzoate
  参考文献：
  名称：

  作为有效原肌球蛋白受体激酶 (TRK) 抑制剂的吲唑氨基喹唑啉衍生物的设计、合成和评估

  摘要：

  原肌球蛋白受体激酶（TRK）是跨膜受体酪氨酸激酶的超家族，自FDA批准Larotrectinib 和 Entrectinib 以来，最近已成为精准抗癌治疗的一种有吸引力的方法。在此，我们报道了一系列新型吲唑氨基喹唑啉和吲唑氨基吲唑作为 TRK 抑制剂的发现。代表性化合物30f对TRK WT 、TRK G595R和TRK G667C表现出良好的抑制活性，IC 50值分别为0.55 nM、25.1 nM和5.4 nM。该化合物还对一组用 NTRK 野生型和突变融合体转化的 Ba/F3 细胞系表现出优于 Larotrectinib 的抗增殖活性（IC 50 = 10–200 nM）。此外，化合物30f表现出良好的体外代谢稳定性（T 1/2 = 73.0 min），表明喹唑啉衍生物可能具有更好的代谢稳定性。最后，通过分子对接预测的化合物30f的结合模式很好地解释了吲唑氨基喹唑啉类化合物作为TRK抑

  DOI：

  10.1016/j.bmc.2024.117608
• 作为产物：
  描述：

  4-氟-2-硝基苯甲酸 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 生成 4-氟-2-硝基苯甲酸甲酯
  参考文献：
  名称：

  Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases

  摘要：

  本发明涉及新的芳基醚磺酰胺及其类似物，其制备方法以及它们用于治疗神经退行性疾病的用途，特别是用于神经退行性疾病的预防和治疗，特别是用于治疗脑卒中和颅脑外伤。

  公开号：

  US06262112B1
• 作为试剂：
  描述：

  碘甲烷 、 4-氟-2-硝基苯甲酸 、 potassium carbonate 、 水 在 氩 、 乙醚 、 Brine 、 Sodium sulfate-III 、 silica gel 、 正己烷 、 4-氟-2-硝基苯甲酸甲酯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 4-氟-2-硝基苯甲酸甲酯
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS

  摘要：

  本发明涉及具有抗癌活性的杂环化合物、含有这种化合物的制药组合物、使用这种化合物和组合物治疗哺乳动物疾病和病症的方法以及它们的制造方法。

  公开号：

  US20090048301A1

文献信息

• QUINAZOLINONES AS PARP14 INHIBITORS
  申请人：Ribon Therapeutics Inc.

  公开号：US20190194174A1

  公开（公告）日：2019-06-27

  The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

  本发明涉及喹唑啉酮和相关化合物，它们是PARP14的抑制剂，例如在癌症和炎症性疾病的治疗中是有用的。
• [EN] THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS OXY-PHÉNYL-ARYLES THÉRAPEUTIQUES ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009053694A1

  公开（公告）日：2009-04-30

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

  本发明总体涉及治疗化合物领域，更具体地涉及如本文所述的某些氧基苯基芳基化合物（以下简称OPA化合物），其中，抑制检查点激酶2（CHK2）激酶功能。本发明还涉及包含此类化合物的药物组合物，以及使用此类化合物和组合物，在体内外抑制CHK2激酶功能，以及治疗由CHK2介导的疾病和状况，包括通过抑制CHK2激酶功能而改善的疾病和状况，等等，包括诸如癌症等增殖性疾病，可选地与另一剂联合使用，例如，（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）针对微管的药剂；（e）电离辐射。
• Fluorodenitrations using tetramethylammonium fluoride
  作者：Nubia Boechat、James H. Clark

  DOI：10.1039/c39930000921

  日期：——

  Tetramethylammonium fluoride activated by azeotropic drying in situ is an efficient reagent for the fluorodenitration of nitroaromatics.

  通过共沸干燥原位活化的四甲基氟化铵是硝基芳族化合物的氟代脱氮的有效试剂。
• Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride
  作者：Pouria H. Jalily、Jodene Eldstrom、Scott C. Miller、Daniel C. Kwan、Sheldon S. -H. Tai、Doug Chou、Masahiro Niikura、Ian Tietjen、David Fedida

  DOI：10.1124/mol.115.102731

  日期：2016.8

  The increasing prevalence of influenza viruses with resistance to approved antivirals highlights the need for new anti-influenza therapeutics. Here we describe the functional properties of hexamethylene amiloride (HMA)–derived compounds that inhibit the wild-type and adamantane-resistant forms of the influenza A M2 ion channel. For example, 6-(azepan-1-yl)- N -carbamimidoylnicotinamide ( 9 ) inhibits amantadine-sensitive M2 currents with 3- to 6-fold greater potency than amantadine or HMA (IC50 = 0.2 vs. 0.6 and 1.3 µ M, respectively). Compound 9 competes with amantadine for M2 inhibition, and molecular docking simulations suggest that 9 binds at site(s) that overlap with amantadine binding. In addition, tert -butyl 4′-(carbamimidoylcarbamoyl)-2′,3-dinitro-[1,1′-biphenyl]-4-carboxylate ( 27 ) acts both on adamantane-sensitive and a resistant M2 variant encoding a serine to asparagine 31 mutation (S31N) with improved efficacy over amantadine and HMA (IC50 = 0.6 µ M and 4.4 µ M, respectively). Whereas 9 inhibited in vitro replication of influenza virus encoding wild-type M2 (EC50 = 2.3 µ M), both 27 and tert -butyl 4′-(carbamimidoylcarbamoyl)-2′,3-dinitro-[1,1′-biphenyl]-4-carboxylate ( 26 ) preferentially inhibited viruses encoding M2(S31N) (respective EC50 = 18.0 and 1.5 µ M). This finding indicates that HMA derivatives can be designed to inhibit viruses with resistance to amantadine. Our study highlights the potential of HMA derivatives as inhibitors of drug-resistant influenza M2 ion channels.

  对核准抗病毒药物产生耐药性的流感病毒日益增多,这凸显了开发新型抗流感药物的必要性。本文描述了六亚甲基氨氯吡嗪(HMA)衍生物的功能特性,它们能抑制A型流感M2离子通道的野生型和金刚烷胺耐药型。例如, 6-( 唑戊吡嗪-1-吡啦达)-N-甲甲喷达吡嗪-氨酸胺(9)对金刚烷胺敏感的M2离子通道电流的抑制效力比金刚烷胺或HMA高3至6倍(IC50分别为0.2、0.6和1.3μM)。化合物9与金刚烷胺竞争抑制M2, 分子对接模拟显示9结合在金刚烷胺结合位点的重叠处。此外, 二（伞形酮基羰基）-2',3-二硝基-[1,1'-苄基]-4-羧酸替丁酯(27)既对敏感型M2有效, 也对编码丝氨酸31突变为天冬酰胺(S31N)的耐药型M2变种有效, 且效力优于金刚烷胺和HMA(IC50分别为0.6μM和4.4μM)。虽然9抑制了编码野生型M2的流感病毒的体外复制(EC50=2.3μM), 但27和二（伞形酮基羰基）-2',3-二硝基-[1,1'-苄基]-4-羧酸替丁酯(26)更倾向于抑制编码M2(S31N)的病毒(各自的EC50分别为18.0和1.5μM)。这一发现表明,可以设计HMA衍生物来抑制金刚烷胺耐药的病毒。我们的研究强调了HMA衍生物作为耐药性流感M2离子通道抑制剂的潜力。
• [EN] MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO<br/>[FR] MOLÉCULES PRÉSENTANT CERTAINES UTILITÉS PESTICIDES, ET INTERMÉDIAIRES, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：DOW AGROSCIENCES LLC

  公开号：WO2021011722A1

  公开（公告）日：2021-01-21

  This disclosure relates to compounds having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such compounds and intermediates used in such processes, compositions containing such compounds, and processes of using such compounds against such pests. These compounds/molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses compounds having the following formula (Formula One and/or Formula One-A).

  这份披露涉及具有杀虫作用的化合物，可用于鞭虫门、节肢动物门和/或软体动物门的害虫，用于生产这种化合物的过程和用于这种过程的中间体，含有这种化合物的组合物，以及使用这种化合物对抗这些害虫的过程。这些化合物/分子可以用作线虫杀剂、螨虫杀剂、杀虫剂、螨虫剂和/或软体动物杀虫剂。本文件披露了具有以下化学式的化合物（化学式一和/或化学式一-A）。